GMR
The Original

GENETIC DETERMINANTS OF DRUG RESPONSE VARIABILITY: A PHARMACOGENOMIC INVESTIGATION

D. Suriya[1], Sridevi Sangeetha K S[2], Dr. Manoj A. Vora[3], Soundarya Kasi[4], Dr. Laxmidhar Maharana[5], Amit Kumar[6], Mr. S. Mohan[7], Dr. Lionel John J[8]

[1]Assistant Professor, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India, Email: suriyaanand3@gmail.com, ORCID: https://orcid.org/0009-0005-6707-7672
[2]Professor, Meenakshi College of Allied Health Sciences, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research
[3]Assistant Professor, Faculty of Science, Gokul Global University, Sidhpur, Gujarat, India,
Email: manojvora.chem.gsc@gokuluniversity.ac.in, ORCID: https://orcid.org/0000-0002-9603-4576
[4]Lecturer, Pharmacognosy, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research
[5]Professor, Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India, Email: laxmidharmaharana@soa.ac.in, ORCID: https://orcid.org/0000-0002-0424-0875
[6]Centre of Research Impact and Outcome, Chitkara University, Rajpura – 140417, Punjab, India, Email: amit.kumar.orp@chitkara.edu.in, ORCID: https://orcid.org/0009-0001-9561-2768
[7]Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation (Deemed to be University), Puducherry, India, Email: mohan.sivanandham@avmc.edu.in, ORCID: https://orcid.org/0000-0001-6905-1023
[8]Professor, Orthopaedics, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research
ORCID: https://orcid.org/0000-0001-5901-3859

ABSTRACT

Individual to individual variance in drugs response is a major issue in clinical therapeutics which may culminate to adverse drug reaction or decreased efficacy. Pharmacogenomics offers a system through which the genetic variations are known to affect drug metabolism, transportation, and interaction with target, hence personalized medicine. The review analyzes the essential hereditary factors of drug response variation, which include in the list of polymorphisms of drug-metabolizing enzymes (e.g., CYP450 family), transporters (ABC and SLC families), and drug targets VKORC1 and EGFR. The up to date findings of pharmacogenomic researches in the cardiovascular, oncological, neurological, and infectious disease are essential to reveal clinically significant drug-gene relationships. Genomic technologies, such as genome-wide association and multi-omics technologies, have led to major improvements in the detection of predictive biomarkers. Also, the accuracy of the prediction of drug responses is being improved with the integration of artificial intelligence and machine learning methods. In spite of these developments, there still are challenges like population bias and limited clinical translation, among others and there are also ethical issues. There is also the assessment of existing clinical guidelines as well as decision-support systems. Visionary perspectives, such as polygenic risk models and precision medicine systems, are presented, which highlights how pharmacogenomics can improve the quality of therapeutic outcomes and promote more personalized treatment plans.

KEYWORDS: Pharmacogenomics, Drug Response Variability, Genetic Polymorphisms, Precision Medicine, Pharmacokinetics, Personalized Therapy

1. INTRODUCTION

One of the fastest-growing sectors at the border of genetics and pharmacology, pharmacogenomics aims to comprehend the effects of personal genetic peculiarities on how people react to drugs (Crews et al., 2012; Relling & Evans, 2015; Pirmohamed, 2023). Due to the emergence of high-throughput genomic technologies and next-generation sequencing, genetic polymorphisms that regulate drug metabolism, transport, and molecular targets have become more and more possible (Chen et al., 2021; Carvalho Henriques et al., 2021). Such genetic variations are vital to predicting the effectiveness and safety of the therapeutic interventions, thus constituting a scientific basis of precision medicine (Crews et al., 2012; Pirmohamed, 2023). Pharmacogenomics has a potential to transform the traditional one-fit-all approaches to treatment by providing individualized choices of drugs and specific doses (Relling and Evans, 2015). The phenotypic difference in the response to drugs is one of the significant clinical practice and drug development challenges (Cacabelos et al., 2021). People who are given an identical drug at the same doses have significantly different treatment outcomes, spanning from the best effects to a complete failure in treatment or a life-threatening adverse drug reaction (ADR) (Cacabelos et al., 2021). This level of inconsistency does not only undermine patient safety, but it also plays a major role in causing a raise in healthcare expenses and length of treatment. Adverse drug reactions in isolation are a primary morbidity and mortality factor globally and are the reason why more tailored treatment plans are in urgent demand (Pirmohamed, 2023). Although environmental, physiological and lifestyle factors, including age, disease status, drug interactions, etc. also determine drug response, genetic determinants are identified as the main causes of this variability (Crews et al., 2012; Relling & Evans, 2015). Genetic differences on the molecular level influence

pharmacodynamics (PD) and pharmacokinetics (PK). Enzymes and transporters with polymorphic genes are predominant pharmacokinetic processes, such as drug absorption, distribution, metabolism, and excretion (ADME) (Gaedigk et al., 2017). An example is that differences in cytochrome P450 (CYP450) family may markedly change the rate of drug metabolism and result in classifications of poor, intermediate, and ultra-rapid metabolizers (Gaedigk et al., 2017). Analogously, genetic variations of drug transporters including those of the ATP-binding cassette (ABC) and solute carrier (SLC) families can also affect bioavailability of drugs and tissue distribution of drugs. Polymorphisms of drug targets, receptors, and signaling pathways may change the sensitivity of drugs and therapeutic response, further adding to inter-patient variability on the pharmacodynamic side (Crews et al., 2012). In the last twenty years, the area of pharmacogenomic research has evolved through candidate gene research to genome-wide association research (GWAS), and, more lately, integrative multi-omics research (Reisberg et al., 2019; Jithesh et al., 2022). The developments have enabled the discovery of a wide range of clinically relevant drug-gene interactions in a wide range of therapeutic fields, including cardiovascular diseases, cancer, neurology and infectious diseases (Van Driest et al., 2014; Reisberg et al., 2019). Although these have been attained, a number of challenges still exist. Numerous pharmacogenomic results have not been replicated in different populations because of genetic heterogeneity and the application of genomic information into clinical practice is not yet common practice (Jithesh et al., 2022; Moyer and Black, 2025). Besides, ethical, legal, and regulatory issues, as well as infrastructural and economic obstacles, still hinder extensive adoption (Pirmohamed, 2023). The growing access to large-scale genomic data and the incorporation of artificial intelligence and machine learning are providing a fresh anew of predicting the response of drugs more accurately (Chen et al., 2021). Such technologies will improve the discovery of new biomarkers and aid in the advanced construction of powerful clinical decision-support systems (Patel et al., 2025). Nevertheless, the delivery of the marked jump between the genomic discovery and clinical application is a critical issue that is necessitated by multidisciplinary collaboration (Moyer and Black, 2025). In this regard, the current review will offer a critical and in-depth review of the genetic determinants of the variability in drug responses. It is a synthesis of the existing research, review of technological developments and discussion of clinical applications, challenges, and future prospects of pharmacogenomics. There is an attempt to make this work contribute to the continuing process of achieving the full realization of genuinely personalized and effective therapeutic strategies by pointing out both the areas where they have been made and the areas where they still need to be done.

2. LITERATURE REVIEW AND EXISTING STATE OF RESEARCH.

The evolution of pharmacogenomics has followed a very dynamic pattern in the past decades, moving away the hypothesis-based candidate gene model to genome-wide and multi-omics methods (Relling & Evans, 2015; Pirmohamed, 2023). Initial research was mainly done to determine single-gene polymorphs linked to drug metabolism, especially in the enzyme family of cytochrome P450 (CYP450) (Gaedigk et al., 2017). The findings of these candidate gene studies were used to establish basic understanding of drug-gene interaction including the effects of CYP2D6, CYP2C9, CYP2C19 polymorphisms in mediating drug metabolism (Gaedigk et al., 2017). They were, however, constrained by the previous biological assumptions and inability to understand the complex genetic architecture in the variability of drug responses. The development of genome-wide association studies (GWAS) represented a paradigm shift as it has made it possible to conduct unbiased discovery of genetic variants in the entire genome (Reisberg et al., 2019). Pharmacogenomic research using GWAS has already been used to discover new loci that are related to drug efficacy and toxicity, as well as abacavir and carbamazepine hypersensitivity, in which HLA alleles are identified to be responsible (Johnson et al., 2017; Martin et al., 2014; Leckband et al., 2013). Regardless of such developments, GWAS methods tend to account only a small proportion of the observed variability, which underlines the polygenic and multifactorial character of drug reaction (Reisberg et al., 2019). In more recent years, transcriptomics, proteomics, metabolomics, and epigenomics methods have been used in integrative forms to allow a better sense of how drugs are responded to (Jithesh et al., 2022). These strategies facilitate the study of the patterns of gene expression, protein interactions, metabolic pathways, and regulation alterations that all affect pharmacokinetic and pharmacodynamic mechanisms. Multi-omics integration has enhanced the discovery of biomarkers and provided insights into the dynamics of biological systems, but issues of data integration and standardization, as well as interpretation, are acute (Pirmohamed, 2023). The important results of earlier research have constantly shown that genetic polymorphism in enzymes, transporters, and drug targets that cannot metabolize drugs is critical in determining the outcomes of therapy (Van Driest et al., 2014). As an example, differences in CYP450 enzymes are closely related with drug metabolism rate, and the transporter polymorphisms of the ABCB1 also affect drug distribution and bioavailability. In like manner, genetic variations in drug targets, such as VKORC1 and EGFR, have also been reported to influence the drug sensitivity and resistance (Johnson et al., 2017). They have resulted in the production of clinically significant pharmacogenomic biomarkers and dosing principles, specifically in cardiovascular and oncology therapies (Scott et al., 2013; Lee et al., 2022; Hicks et al., 2017). In spite of these developments, there are a number of shortcomings in the current state of research, pharmacogenomics. One of the significant issues is that genomic studies are not diversified in terms of population, and people of European descent are overrepresented (Jithesh et al., 2022). Such bias restricts the external validity of the results and can be a source of health inequalities in the use of pharmacogenomics. Also, most studies are limited by small sample sizes, which diminish statistical power and reproducibility (Reisberg et al., 2019). The intricate interaction among genetic and non-genetic factors, including

environmental factors, comorbidity, and drug interactions are frequently not used properly, which makes the results interpretation more complicated. The gap in the genomic discovery and clinical implementation is also another limitation that is critical. Despite many pharmacogenomic associations, a few of them have been implemented into clinical practice because of the lack of validation, standardized guidelines, and infrastructural limitations (Moyer and Black, 2025; Patel et al., 2025). More so, ethical and regulatory issues, such as data privacy and informed consent, still remain barriers to mass adoption (Pirmohamed, 2023). On the basis of these observations, it is possible to point out a number of research gaps. It is urgently required that large-scale, multi-ethnic studies enhance the inclusiveness and the applicability of pharmacogenomic results (Jithesh et al., 2022). Also, the combination of multi-omics data with more complex computational tools, including artificial intelligence and machine learning, has not been fully explored (Chen et al., 2021). Another area of future research to be pursued is the development of powerful clinical decision-supporting systems and the validation of pharmacogenomic biomarkers in clinical practice (Patel et al., 2025; Moyer and Black, 2025). It is important to fill these gaps in order to bring pharmacogenomics to its full potential in personalized medicine.

3. MECHANISMS OF DRUG RESPONSE VARIABILITY

3.1 Pharmacokinetic and Pharmacodynamic Mechanisms

Two processes, pharmacokinetics (PK) and pharmacodynamics (PD), are the main determinants of drug response variability. Pharmacokinetics refers to the effect of the body on a drug in terms of absorption, distribution, metabolism, and excretion (ADME) and pharmacodynamics describes the process of interaction between the drug and the biological targets to produce therapeutic effect. These differences play an important role in the disparity in the efficacy and safety of different drug people. The issue of pharmacokinetic variability is important in determining the concentration of the drug at the site of action. Significant contributors are genetic polymorphisms in drug-metabolizing enzymes especially those that belong to the cytochrome P450 (CYP450) family. Different phenotypes of the metabolizer are associated with variants of genes like CYP2D6, CYP2C9, and CYP2C19 to identify poor metabolizer, intermediate and ultra-rapid metabolizers. Such differences affect the rates of drug clearance leading to either accumulation or toxicity of drugs or less effect of the drug on treatment. An example is that a poor metabolizer will have an adverse effect because the drug levels are high whereas a ultra-rapid metabolizer will not attain a sufficient drug exposure. Transporters of drugs also manipulate pharmacokinetics by controlling drug transport over biological membranes. Drug absorption, distribution, and elimination are regulated by proteins that are encoded by ATP-binding cassette (ABC) and solute carrier (SLC) families. Drug bioavailability and tissue distribution through poly-morphic gene including ABCB1 might change the outcome of the treatment. Variations in drug targets, receptors and signaling pathways identify the pharmacodynamic variability. The genetic differences have the potential to change the receptor structure, expression or affinity of the binding causing alteration in drug sensitivity. As an illustration, the response of patients to warfarin is affected by polymorphism in VKORC1, and the response to targeted cancer treatments is affected by the mutations in EGFR. Also, changes in intracellular signaling components have the potential to alter downstream responses, which also participate in heterogeneous clinical outcomes. The pharmacodynamics and pharmacokinetics are closely interdependent. Drug metabolism may change to cause changes in drug concentration, thus, affecting receptor interaction and therapeutic response. Such a complicated interplay defines the need to combine both PK and PD views in pharmacogenomic studies. In general, the variability of drug response is a complex of both pharmacokinetic and pharmacodynamic changes, the major cause of which is genetic differences in enzymes, transporters, and drug targets. The awareness of these mechanisms is critical in the prediction of the individual responses, as well as in the development of personalized medicine.

3.2 Genetic Determinants

Genetic determinants have been found to play a key role in controlling the variation in drug response by altering key elements that take part in drug metabolism, transport and target interaction. The differences in the genes expressing these parts may have great impact on pharmacokinetics and pharmacodynamics and thus on treatment efficacy and safety. One of the most important genetic factors of drug response is represented by drug-metabolizing enzymes. It is the cytochrome P450 (CYP450) enzyme family which has found significant research in the metabolism of numerous drugs. Enzyme genetic polymorphisms include CYP2D6, CYP2C9, CYP2C19 which create different phenotypes of metabolizers, poor, intermediate, extensive, and ultra-rapid. These phenotypic variations have a direct influence on the drug clearance and plasma concentration level. An example is apprehension of drug build-up and toxicity as the enzyme are less active, or quick excretion of the drug and ensuing lower efficacy as the drug excretion rate is augmented. Besides metabolic enzymes, the drug transporters are also important in the absorption of drugs, distribution, and excretion. The transportation across cellular membranes of drugs is controlled by the action of transporter proteins, especially the ones, which belong to the families of ATP-binding cassettes (ABC) and solute carriers (SLC). Transporter genes, including, ABCB1 and SLCO1B1, may vary genetically, which may alter drug bioavailability and tissue-specific distribution. Such differences are particularly critical in case of drugs with narrow therapeutic indices, the changes in drug concentration even on a minor scale have a considerable clinical impact. The other important type of genetic determinants is drug targets. Drug binding affinity, receptor expression, or downstream signaling pathways can be altered by variations in genes encoding drug targets (receptors and enzymes and signalling molecules). As an

illustration, polymorphisms of VKORC1 gene have an influence on warfarin sensitivity requiring modification of dose, and the mutation of EGFR gene on the response to targeted cancer treatment. These genetic variations may cause variability in drug efficacy, resistance or toxicity. All in all, genetic determinants in the form of drug-metabolizing enzymes, drug targets, and transporters play an important role in enhancing inter-individual variability in drug response. This knowledge of these genetic factors is needed in order to discover predictive biomarkers and build individualized treatment plans.

3.3 Non-Genetic Modifiers

Despite the fact that genetic variation forms a significant source of inter-individual variation in drug response, non-genetic modifiers also possess a significant contribution to the results of therapeutic processes. These may change pharmacodynamic and pharmacokinetic actions and may enhance or diminish the impact of genetic determinants underlying them. Epigenetic regulation, environmental exposures, and the human microbiome are some of the most potent non-genetic modifiers and they are known to cause variation in the efficacy, toxicity, and failure of the medication. Epigenetic activity controls gene activity, but not the underlying DNA sequence and thus is a significant degree of control on drug-response pathways. Gene expression of drug-metabolizing enzymes, drug transporters and receptors can be affected by DNA methylation, histone changes and non-coding RNAs. Indicatively, the pattern of changes in methylation can either suppress or activate the transcription of cytochrome P450 enzymes, thus altering the metabolic capacity of people of the same genetic background. Similarly, microRNAs have the potential to regulate the post-transcriptional expression of genes and shape cell response towards therapeutic agents. By so doing, epigenetic regulation serves as an active point of interaction between hereditary genetic structure and external stimuli. As Figure 1 shows, the response of drugs is not only defined by predetermined genetic factors but also by regulative and physiological adjusters that transform the pharmacodynamics behavior and pharmacokinetics. Drug response variability is also caused by environmental factors due to their influence on metabolism, absorption and sensitivity of the cell. One of the most widespread modifiers is diet because some foods and nutrients can activate or suppress the activities of the enzymes, hence changing the plasma concentrations of drugs. Drug disposition and therapeutic response can also be influenced by smoking, drinking alcohol or exposure to pollutants, and lifestyle related habits. Moreover, disease condition, organ dysfunction, and co-morbid drugs can alter enzyme and transporter activity, which can produce clinically significant variation. In particular, drug-drug interactions are one of the primary reasons behind the change in the therapeutic outcome due to the possibility of modification of the bioavailability or clearance of co-administered drugs. Another significant non-genetic drug response determinant has been the gut microbiome. Gastrointestinal tract microbial communities are able to directly metabolise drugs or modify their bioavailability or produce metabolites which have divergent pharmacological actions. The microbiome can also impact the host immune response and inflammatory signaling and hence drug sensitivity and toxicity. As the composition of microbiomes differs significantly in different individuals, and is determined by diet, age, health and antibiotic exposure, it adds another level of complexity to personalized therapy. All in all, non-genetic modifiers have a close association with inherited genetic factors in determining the results of treatment. Their collective effect strengthens the necessity to have an integrated pharmacogenomic model instead of simply focused on genes explanation of drug response. Table 1, on this basis, provides a summary of the key pharmacogenes examined in this section and the previous subsections along with their functional role in drug metabolism, drug transport, and drug target response.



Figure 1. Integrated Framework of Genetic and Non-Genetic Influences on Drug Response Variability

The figure demonstrates how genetic components (drug-metabolizing enzymes, drug-transporters, and drug targets) and non-genetic modifiers (environment, physiology and regulatory/epigenetic processes) interact to affect individual drug response. These two types have an independent and a combined effect on the pharmacokinetic (absorption, distribution, metabolism, and excretion) and pharmacodynamic (drug target interaction and downstream signaling) processes. The combination of these mechanisms eventually determines clinical outcomes as therapeutic efficacy, adverse drug reactions, toxicity, and treatment failure.

Table 1. Key pharmacogenes and their functional roles

Pharmacogene	Encoded protein/function	Category	Representative clinical relevance

CYP2D6	Drug-metabolizing enzyme involved in oxidation of many drugs	Metabolizing enzyme	Alters response to antidepressants, antipsychotics, opioids
CYP2C9	Enzyme involved in metabolism of warfarin and other drugs	Metabolizing enzyme	Influences warfarin dose requirement and bleeding risk
CYP2C19	Enzyme involved in metabolism of clopidogrel and proton pump inhibitors	Metabolizing enzyme	Affects antiplatelet response and treatment efficacy
TPMT	Thiopurine S-methyltransferase enzyme	Metabolizing enzyme	Determines thiopurine toxicity risk
DPYD	Dihydropyrimidine dehydrogenase enzyme	Metabolizing enzyme	Associated with fluoropyrimidine toxicity
ABCB1	P-glycoprotein drug efflux transporter	Transporter	Modifies drug absorption, distribution, and resistance
SLCO1B1	Hepatic uptake transporter OATP1B1	Transporter	Linked to statin transport and myopathy risk
VKORC1	Vitamin K epoxide reductase complex subunit 1	Drug target	Determines warfarin sensitivity
EGFR	Epidermal growth factor receptor	Drug target	Predicts response to targeted cancer therapy
HLA-B alleles	Immune recognition molecules	Immune-associated determinant	Associated with severe hypersensitivity reactions to specific drugs

4. Pharmacogenomic Variants and Disease-Specific Applications

The recent studies of pharmacogenomics have revealed hundreds of drug-gene interactions of clinical interest in various therapeutic domains, and show the significance of genetic variation in determining a customized way of treatment. These links are especially made out in cardiovascular diseases, oncology, neurology, psychiatry, and infectious diseases wherein genetic profiling has helped tremendously in better treatment and reduction of side effects. Genetic variations in cardiovascular pharmacogenomics have been of great importance in predicting the response of patients towards drugs that are regularly used like warfarin and clopidogrel. The CYP2C9 and VKORC1 genes are polymorphic and contribute significantly to the warfarin metabolism and sensitivity, and therefore, patients require a tailored dose in order to minimize the risk of bleeding complications. On the same note, CYP2C19 variants influence the activation of clopidogrel, where loss of function alleles have been linked to less antiplatelet effect and more risk of cardiovascular outcomes. Pharmacogenomics has been extensively used in oncology to maximize chemotherapy and targeted therapy. TPMT gene variants have been reported to determine the thiopurine drug metabolism in which decreased enzyme activity may result in excessive toxicity. Similarly, DPYD gene-related mutations in which the protein is the dihydropyrimidine dehydrogenase are linked to resistance to the toxicity of fluoropyrimidine-based chemotherapeutics. Such discoveries have contributed to the introduction of genetic screening before the onset of treatment in most clinical practice. There is also a high pharmacogenomic variation in neurology and psychiatry, especially in the metabolism of psychotropic drugs. CYP2D6 enzyme is a central metabolite in the metabolism of antidepressants, antipsychotics, and opioids, the genetic polymorphism of which affects the effectiveness of different drugs and the presence of adverse events. There are also certain human leukocyte antigen (HLA) types that are highly linked with the extreme reaction to drugs like carbamazepine, including HLA-B1502, very common in some ethnic groups. Pharmacogenomic knowledge has been useful in enhancing the safety of the drug in the context of infectious diseases. The documented example is the correlation of HLA-B5701 allele with the abacavir antiretroviral drug-induced hypersensitivity. Pre-therapy screening of this allele has become a standard clinical practice and this has dramatically decreased cases of severe adverse reactions. All these illustrations highlight the potential of pharmacogenomic testing, which is relevant to clinical practice in the optimization of drug therapy in a variety of disease conditions. Genetic information offers the best solution by increasing the effectiveness of treatments and reducing the amount of toxicity. Table 2 provides a summary of major drug-gene interactions and clinical implications of these drugs in these areas of treatment.

Table 2. Drug–Gene Associations and Clinical Relevance

Drug	Gene	Disease Area	Clinical Impact
Warfarin	CYP2C9, VKORC1	Cardiovascular	Dose adjustment to prevent bleeding
Clopidogrel	CYP2C19	Cardiovascular	Reduced efficacy in poor metabolizers
Thiopurines	TPMT	Oncology	Risk of severe toxicity with low enzyme activity

Fluoropyrimidines	DPYD	Oncology	Increased toxicity in deficient patients
Antidepressants / Antipsychotics	CYP2D6	Neurology/Psychiatry	Altered metabolism affecting efficacy and safety
Carbamazepine	HLA-B*1502	Neurology	Risk of severe hypersensitivity reactions
Abacavir	HLA-B*5701	Infectious Diseases	Hypersensitivity reaction risk

5. Clinical Implementation of Pharmacogenomics

Clinical application of pharmacogenomics is a significant milestone towards applying genetic findings in the process of developing individualized treatments. Genetic information can help healthcare professionals to maximize the use of drugs, dosages, and safety in clinical practice thus enhancing patient outcomes and minimizing adverse drug reactions. Pharmacogenomic implementation is based on biomarker-guided therapy, in which genetic variants are the basis to use to influence treatment decisions. Biomarkers that are clinically validated, e.g., CYP2C19 clopidogrel response or HLA-B alleles hypersensitivity to drugs can allow clinicians to customize treatments depending on the particular genetic makeup. It is beneficial in improving the therapeutic efficacy and reducing toxicity especially in drugs with a narrow therapeutic indices.

Organizations (including Clinical Pharmacogenetics Implementation Consortium (CPIC), the U.S. Food and Drug Administration (FDA), and the Dutch Pharmacogenetics Working Group (DPWG)) have developed clinical guidelines, which are standardized recommendations on how pharmacogenomic data should be incorporated into clinical practice. These recommendations provide evidence-based dosing corrections and drug choices plans depending on particular genetic variations, which allows the uniform and dependable implementation in healthcare facilities. The clinical decision support systems (CDSS) are of key interest in bringing pharmacogenomics to the operation of a healthcare setting. These systems are also known as genetic test results integrated with electronic health records (EHRs), that offer real-time and patient-specific recommendations to clinicians. CDSS tools have the potential to lessen the cognitive load and increase clinical decision-making accuracy by automating the interpretation of complicated genomic data by caregivers. Pharmacogenomics implementation in healthcare systems needs the effective infrastructure, such as the availability of genetic tests, standard data formats, and cross-disciplinary teams of clinicians, geneticists, and informaticians. Moreover, a lack of cost, privacy of data, and general awareness of clinicians should be overcome and make it widespread. Irrespective of these obstacles, the current improvements in digital health technologies and the growing access to genomic data are facilitating the integration of pharmacogenomics into the standard clinical practice. Figure 2 represents the overall clinical process of pharmacogenomics-based customized therapy by considering all the steps involved in patient evaluation, genetic testing, and clinical decision-making, optimization of therapy, and monitoring of outcomes.



Figure 2. Clinical Workflow for Pharmacogenomics-Based Personalized Therapy

The figure below suggests the clinical workflow to apply pharma-genomics in individual therapy. It starts by patient assessment, which is then followed by genetic testing by sample collection, genotyping or sequencing. The resultant data is interpreted and analyzed with the pharmacogenomic databases in order to aid in making clinical decisions on the basis of given guidelines including CPIC and FDA recommendations. Individualized treatment is then adopted by involving selection of drugs and their dosages. Workflow ends with monitoring and clinical follow-up to assess the response to treatment and adverse effects to optimize patient outcomes through fine-tuning of treatment.

6. TECHNOLOGIES AND COMPUTATIONAL APPROACHES

The progress in genomic technologies and computational tools has made the research of pharmacogenomics much faster and helped increase the comprehension of variability of drug response and elaborate the approach to individualized therapy. These technologies include genotyping and sequencing technology, genome-wide association study (GWAS), integration of multi-omics, and artificial intelligence (AI) and machine learning (ML) technology. Pharmacogenomic analysis is based on genotyping and sequencing technology because it allows the detection of genetic variations that relate to drug response. Genotyping systems, including single nucleotide polymorphism (SNP) arrays can be used to identify variants of interest quickly and affordably, whereas next-generation sequencing (NGS) methods, e.g., whole-exome and whole-genome sequencing, can be used to gain comprehensive knowledge on common and rare variants. These methods have greatly enhanced the accuracy and resolution of the pharmacogenomic studies.

Genome-wide association studies (GWAS) have further extended the pharmacogenomics into unexplored areas, where genetic loci can be unbiasedly determined to relate with drug efficacy and toxicity. GWAS has the capability of identifying new drug-gene relationships not identified using candidate gene methods through the analysis of large cohorts. Nonetheless, the GWAS results can only justify a part of the variability that they observe and might need to be verified in different populations. Multi-omics information Multi-omics incorporation, such as the incorporation of transcriptomics, proteomics, metabolomics, and epigenomics, has proven to be an effective measure of the complicated biological pathways of drug responsiveness. Multi-omics analysis can be used to study the pattern of gene expression, protein interactions and metabolic pathways in a more holistic view of pharmacological processes. Nonetheless, the issues of data integration, standardization and computational complexity are also a big problem, despite its potential. Pharmacogenomics is progressively being utilized with artificial intelligence and machine learning methods to facilitate predictive modeling and clinical decision-making. They can be used to analyze high and large-scale datasets to discover patterns and predict individual responses to drugs of a drug with more accurate results. Genomic data plus clinical data are also easily combined using AI/ML methods, which contribute to the creation of individual treatment plans. Nevertheless, some issues like model interpretability, data quality, and bias have to be addressed to have reliable implementation. Table 3 provides a comparative description of these pharmacogenomic technologies, their principles, strengths, and shortcomings.

Table 3. Comparison of Pharmacogenomic Technologies

Technology	Principle	Advantages	Limitations
Genotyping (SNP arrays)	Detection of known genetic variants	Cost-effective, high-throughput, rapid analysis	Limited to predefined variants
Next-Generation Sequencing (NGS)	Comprehensive sequencing of DNA (WES/WGS)	Detects rare and novel variants, high resolution	High cost, large data complexity
GWAS	Genome-wide scanning for variant associations	Identifies novel loci, unbiased approach	Requires large sample sizes, limited explanatory power
Multi-omics Integration	Combines genomics, transcriptomics, proteomics, metabolomics	Holistic understanding of biological systems	Data integration challenges, computational complexity
AI/ML Approaches	Data-driven predictive modeling	High predictive accuracy, handles large datasets	Interpretability issues, potential bias

7. CHALLENGES AND FUTURE DIRECTIONS

Even though considerable progress has been made in the area of pharmacogenomics, a number of scientific, clinical and regulatory issues still make the adoption of this technology in the usual health care practice rather limited. The challenges mentioned above are critical to the achievement of the full potential of personalized medicine. Scientifically, the complexity and multifactorial nature of drug response is one of the main challenges. Many genetic variants have been described, although they can usually just describe a part of the apparent variability. The interaction among several genes, environmental conditions, and physiological conditions affects drugs response and it is not easy to provide predictive models of a drug. Also, the majority of pharmacogenomic studies are carried out in the population of European descent, which means that the outcomes are not extensively applicable in the context of other ethnicities. The absence of big, multi-ethnic data also makes it difficult to find the biomarkers, which could be universal.

There are also obstacles of clinical implementation. Even though there are multiple pharmacogenomic associations that have been confirmed, they are not fully implemented into clinical practice. Issues such as poor awareness of the clinicians and absence of uniform testing guidelines and inadequate data management infrastructure are also problems. Moreover, decoding sophisticated genetic data might be done only with a specific set of skills, which might not be easily obtained in the context of clinical practice. Genetic testing is also not very affordable, and access is limited due to insufficient level of reimbursements especially in resource constrained settings. There is also another important aspect of pharmacogenomics, which are ethical and regulatory concerns. Genetic data utilization poses the risks of patient privacy, data security, or informed consent. It is a major challenge to ensure that genomic information is made non-disclosed with an option of making it useful in clinics. The regulatory frameworks should also be updated to take care of data sharing problems, standardisation problems, and the validation of tests of pharmacogenomic. Moreover, the differences in the access to genomic technologies can strengthen the existing healthcare disparities. In the future, there are a number of emerging trends that can be used to provide solutions to these challenges. Artificial intelligence and machine learning could help improve the predictability of the result as they find patterns in drug reaction that are not consistently obvious in high-dimensional datasets. The development of genome editing technologies including CRISPR-Cas systems allows not only functionally validating pharmacogenomic variants but also getting a better understanding of gene-drug interactions. Furthermore, the emergence of polygenic risk models including the combined effect of multiple

genetic variants is more of an overall approach to drug response prediction than any single-gene analysis. Moreover, the growing accessibility of multi-omics information and practical clinical datasets should also facilitate the transfer of pharmacogenomic discoveries into clinical practice. The overcoming of the current barriers will be important with the strengthening of interdisciplinary collaboration with clinicians, geneticists, bioinformaticians, and policymakers. Finally, it is possible to overcome these issues and utilize new technologies, which will lead to more accurate, fair, and efficient pharmacogenomic-based treatments.

8. TRANSLATIONAL IMPACT AND CONCLUSION

The adoption of pharmacogenomics in clinical practice can radically change the nature of healthcare in contemporary societies because it allows more specific and personalized treatment approaches. Among the most prominent clinical outcomes is the decrease in adverse drug reactions (ADRs), which is one of the primary causes of morbidity and death on the global scale. Clinicians can maximize drug choice and dose to enhance treatment effectiveness and safety by determining patient-specific genetic variations that impact drug metabolism, transport, and target interactions. Pharmacogenomics can also improve the effectiveness of therapy since it limits trial and error prescribing specifically when dealing with complex diseases like cancer, heart diseases, and nerve diseases. Economically, pharmacogenomics implementation has significant long-term advantages despite the short-term cost of genetic testing, and development of infrastructure. Individualized therapy will decrease hospitalization, decrease emergency serious adverse events, and decrease use of non-effective treatment, which will eventually reduce total healthcare spending. Moreover, the efficacy of drugs and decreased failures of treatment results in increased productivity and quality of life of patients and creates more socioeconomic benefits. With a further decline in the prices of the genomic technologies, which will become more accessible to the general population, the cost-effectiveness of pharmacogenomic-guided therapy is likely to become even more affordable. To sum up, pharmacogenomics is a key breakthrough in the shift to precision medicine that provides an all-encompassing framework of drug response variability understanding and management. Even though considerable success has been achieved in the identification of supporting technologies and clinically meaningful genetic determinants, all issues of implementation, data integration, and ethics are still present. These challenges will be required to be addressed by an interdisciplinary approach, technological development, and effective policy frameworks to reach the mass clinical adoption stage. Conclusively, further development of pharmacogenomics has the potential to provide safer, more efficient, and patient-centered healthcare services.

REFERENCES

1. Cacabelos, R., Naidoo, V., Corzo, L., Cacabelos, N., & Carril, J. C. (2021). Genophenotypic factors and pharmacogenomics in adverse drug reactions. International Journal of Molecular Sciences, 22(24), 13302.
2. Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T. M., ... & Callaghan, J. T. (2014). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clinical Pharmacology & Therapeutics, 96(5), 542-548.
3. Chen, X., Shen, F., Gonzaludo, N., Malhotra, A., Rogert, C., Taft, R. J., ... & Eberle, M. A. (2021). Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. The Pharmacogenomics Journal, 21(2), 251-261.
4. Crews, K. R., Hicks, J. K., Pui, C. H., Relling, M. V., & Evans, W. E. (2012). Pharmacogenomics and individualized medicine: translating science into practice. Clinical Pharmacology & Therapeutics, 92(4), 467-475.
5. Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., ... & Skaar, T. C. (2021). Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clinical Pharmacology & Therapeutics, 110(4), 888-896.
6. Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., & Leeder, J. S. (2017). Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 19(1), 69-76.
7. Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., ... & Stingl, J. C. (2017). Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical Pharmacology & Therapeutics, 102(1), 37.
8. Jithesh, P. V., Abuhaliqa, M., Syed, N., Ahmed, I., El Anbari, M., Bastaki, K., ... & Pirmohamed, M. (2022). A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genomic Medicine, 7(1), 10.
9. Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., ... & Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics, 102(3), 397-404.
10. Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., ... & Shuldiner, A. R. (2022). Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959-967.
11. Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George Jr, A. L., Tran, E., Berger, R., ... & Pirmohamed, M. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clinical Pharmacology & Therapeutics, 94(3), 324-328.

12. Martin, M. A., Hoffman, J. M., Freimuth, R. R., Klein, T. E., Dong, B. J., Pirmohamed, M., ... & Kroetz, D. L. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clinical Pharmacology & Therapeutics, 95(5), 499-500.
13. Moyer, A. M., & Black, J. L. (2025). Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities. Annals of Laboratory Medicine, 45(3), 247-258.
14. Patel, T. J., Wehbe, E., Hughes, S., Patanwala, A. E., Kritharides, L., Lal, S., ... & Stocker, S. L. (2025). Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services. The Pharmacogenomics Journal, 25(3), 12.
15. Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 24(6), 350-362.
16. Reisberg, S., Krebs, K., Lepamets, M., Kals, M., Mägi, R., Metsalu, K., ... & Milani, L. (2019). Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in Medicine, 21(6), 1345-1354.
17. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343-350.
18. Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., ... & Shuldiner, A. R. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics, 94(3), 317-323.
19. Van Driest, S. L., Shi, Y., Bowton, E. A., Schildcrout, J. S., Peterson, J. F., Pulley, J., ... & Roden, D. M. (2014). Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clinical Pharmacology & Therapeutics, 95(4), 423-431.
20. Carvalho Henriques, B., Buchner, A., Hu, X., Wang, Y., Yavorskyy, V., Wallace, K., ... & Aitchison, K. J. (2021). Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry, 11(1), 596.